Peter Thompson Biography and Net Worth

Director of Corvus Pharmaceuticals

Dr. Thompson is currently a Member at OrbiMed Advisors LLC and has over 20 years of industry experience. He co-founded and was CEO of Trubion Pharmaceuticals and serves as a director on the boards of several public and private companies. He previously held executive positions at Chiron Corporation and Becton Dickinson. Dr. Thompson is an Ernst & Young Entrepreneur of the Year awardee, an Affiliate Professor of Neurosurgery at the University of Washington, an inventor on numerous patents, and a board-certified internist and oncologist.

What is Peter A. Thompson's net worth?: The estimated net worth of Peter A. Thompson is at least $31.69 million as of November 26th, 2025. Dr. Thompson owns 3,596,886 shares of Corvus Pharmaceuticals stock worth more than $31,688,566 as of December 5th. This net worth approximation does not reflect any other assets that Dr. Thompson may own. Additionally, Dr. Thompson receives a salary of $47,000.00 as Director at Corvus Pharmaceuticals. Learn More about Peter A. Thompson's net worth.
How old is Peter A. Thompson?: Dr. Thompson is currently 64 years old. There are 3 older executives and no younger executives at Corvus Pharmaceuticals. The oldest executive at Corvus Pharmaceuticals is Dr. Richard A. Miller M.D., Co-Founder, President, CEO & Chairman of the Board, who is 73 years old. Learn More on Peter A. Thompson's age.
What is Peter A. Thompson's salary?: As the Director of Corvus Pharmaceuticals, Inc., Dr. Thompson earns $47,000.00 per year. There are 3 executives that earn more than Dr. Thompson. The highest earning executive at Corvus Pharmaceuticals is Mr. Leiv Lea, Chief Financial Officer, who commands a salary of $400,210.00 per year. Learn More on Peter A. Thompson's salary.
How do I contact Peter A. Thompson?: The corporate mailing address for Dr. Thompson and other Corvus Pharmaceuticals executives is 863 Mitten Road Suite102, BURLINGAME CA, 94010. Corvus Pharmaceuticals can also be reached via phone at (650) 900-4520 and via email at [email protected]. Learn More on Peter A. Thompson's contact information.
Has Peter A. Thompson been buying or selling shares of Corvus Pharmaceuticals?: Peter A. Thompson has not been actively trading shares of Corvus Pharmaceuticals in the last ninety days. Most recently, Peter A. Thompson sold 1,176,332 shares of the business's stock in a transaction on Friday, June 27th. The shares were sold at an average price of $4.16, for a transaction totalling $4,893,541.12. Following the completion of the sale, the director now directly owns 7,165,006 shares of the company's stock, valued at $29,806,424.96. Learn More on Peter A. Thompson's trading history.
Who are Corvus Pharmaceuticals' active insiders?: Corvus Pharmaceuticals' insider roster includes William Jones (SVP, Pharmaceutical Development), Richard Miller (CEO), and Peter Thompson (Director). Learn More on Corvus Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Corvus Pharmaceuticals?: During the last year, insiders at the sold shares 1 times. They sold a total of 1,176,332 shares worth more than $4,893,541.12. The most recent insider tranaction occured on June, 27th when Director Peter A Thompson sold 1,176,332 shares worth more than $4,893,541.12. Insiders at Corvus Pharmaceuticals own 28.5% of the company. Learn More about insider trades at Corvus Pharmaceuticals.
Information on this page was last updated on 6/27/2025.

Peter A. Thompson Insider Trading History at Corvus Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/27/2025	Sell	1,176,332	$4.16	$4,893,541.12	7,165,006
6/27/2019	Buy	32,923	$3.34	$109,962.82
6/10/2016	Buy	50,000	$12.96	$648,000.00
5/19/2016	Buy	6,800	$11.77	$80,036.00
3/29/2016	Buy	550,000	$15.00	$8,250,000.00

Peter A. Thompson Buying and Selling Activity at Corvus Pharmaceuticals

Corvus Pharmaceuticals Company Overview

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Today's Range

Now: $8.81

$8.40

$8.90

50 Day Range

MA: $7.84

$6.87

$9.09

2 Week Range

Now: $8.81

$2.54

$9.32

Volume

1,224,996 shs

Average Volume

888,820 shs

Market Capitalization

$657.93 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.64

Peter Thompson Biography and Net Worth

What is Peter A. Thompson's net worth?

How old is Peter A. Thompson?

What is Peter A. Thompson's salary?

How do I contact Peter A. Thompson?

Has Peter A. Thompson been buying or selling shares of Corvus Pharmaceuticals?

Who are Corvus Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Corvus Pharmaceuticals?